Table S2.
Subgroup analysis for FPG of various variables
| Group | Number of studies | WMD (95% CI) | P for heterogeneity | I2 % |
| Total | 7 | -0.19 [-0.42, 0.05] | < 0.001 | 93.00 |
| PG | 94.00 | |||
| NGR | 4 | -0.33 [-0.95, 0.29] | < 0.001 | 93.70 |
| IGT or DM | 3 | -0.12 [-0.42, 0.19] | < 0.001 | 91.20 |
| Dosage | ||||
| Allopurinol ≥ 300 mg/d | 3 | -0.53 [-0.74, -0.32] | 0.217 | 34.60 |
| Allopurinol < 300 mg/d | 2 | 0.10 [0.07, 0.13] | 0.688 | 0 |
| Benzbromarone 50 mg/d | 1 | -0.33 [-0.56, -0.10] | - | - |
| Adjust according to SUA | 1 | 0.01 [-0.11, 0.13] | - | - |
| Mean SUA at baseline | ||||
| ≥ 420 umol/L | 4 | -0.17 [-0.61, 0.27] | < 0.001 | 92.00 |
| < 420 umol/L | 3 | -0.20 [-0.58, 0.18] | < 0.001 | 94.00 |
| Reduction of SUA | ||||
| ≥ 150 umol/L | 3 | -0.29 [-0.99, 0.41] | < 0.001 | 96.00 |
| < 150 umol/L | 4 | -0.13 [-0.38, 0.11] | < 0.001 | 85.00 |
| Mean age | ||||
| ≥ 50 years | 5 | -0.13 [-0.34, 0.07] | < 0.001 | 88.80 |
| < 50 years | 2 | -0.26 [-1.07, 0.56] | < 0.001 | 94.10 |
| BMI | ||||
| ≥ 28 | 3 | -0.15 [-0.62, 0.31] | < 0.001 | 91.00 |
| < 28 | 3 | -0.05 [-0.29, 0.20] | < 0.001 | 99.00 |
| Duration | ||||
| ≥ 6 months | 3 | -0.33 [-0.95, 0.29] | < 0.001 | 93.70 |
| < 6 months | 4. | -0.12 [-0.42, 0.19] | < 0.001 | 91.20 |
| Number of participant | ||||
| >60 | 4 | -0.07 [-0.28, 0.13] | < 0.001 | 87.10 |
| ≤60 | 3 | -0.29 [-0.72, 0.14] | < 0.001 | 88.60 |
Abbreviations: PG, plasma glucose; NGR, normal glucose regulation; IGT, impaired glucose tolerance; DM, diabetes mellitus; SUA, serum uric acid; BMI, body mass index.